2,004 results match your criteria Bailliere\'s clinical gastroenterology[Journal]


Palliation of dysphagia.

Best Pract Res Clin Gastroenterol 2018 Oct - Dec;36-37:97-103. Epub 2018 Nov 22.

Department of Gastroenterology & Hepatology, Erasmus MC University Medical Centre, Rotterdam, the Netherlands. Electronic address:

Palliation of dysphagia is the cornerstone of palliative treatment in patients with incurable oesophageal cancer. Available palliative options for dysphagia are oesophageal stent placement and radiotherapy. In general, oesophageal stent placement is the preferred therapeutic option in patients with a relatively poor prognosis because of its rapid relief of dysphagia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2018.11.010DOI Listing
January 2019

The role of surgery in advanced disease for esophageal and junctional cancer.

Best Pract Res Clin Gastroenterol 2018 Oct - Dec;36-37:91-96. Epub 2018 Nov 24.

Department of Surgery, Erasmus MC - University Medical Center Rotterdam, PO BOX 2040, 3000, CA, Rotterdam, the Netherlands. Electronic address:

The incidence of esophageal and junctional cancer has been increasing in western industrialized nations in the past 30 years. At the time of diagnosis, approximately 50% of patients with esophageal and junctional cancers have distant metastases and are considered incurable. In the recent ESMO guidelines and the German S3 guidelines, surgical therapy for metastatic disease is not recommended. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2018.11.002DOI Listing
January 2019

Molecular pathways in the development and treatment of oesophageal cancer.

Best Pract Res Clin Gastroenterol 2018 Oct - Dec;36-37:9-15. Epub 2018 Nov 23.

Cancer Research UK and Royal College of Surgeons of England Advanced Clinician Scientist Fellow, University of Southampton, UK. Electronic address:

The molecular pathways involved in the development and treatment of oesophageal cancer are complex. Recent large-scale genome sequencing studies have delivered novel insights into aetiology and possible targeted treatments. Oesophageal squamous cell carcinoma (OSCC) and adenocarcinoma (OAC) are distinct entities. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15216918183012
Publisher Site
http://dx.doi.org/10.1016/j.bpg.2018.11.013DOI Listing
January 2019
14 Reads

The management of mid & proximal oesophageal squamous cell carcinoma.

Authors:
Ian Wong Simon Law

Best Pract Res Clin Gastroenterol 2018 Oct - Dec;36-37:85-90. Epub 2018 Nov 30.

Division of Esophageal and Upper Gastrointestinal Surgery, Department of Surgery, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong. Electronic address:

Despite the rise in incidence of adenocarcinoma, squamous cell cancer of the oesophagus remains the commonest cell type worldwide and is predominant in the East. Except for very early tumours where endoscopic therapy can be performed with curative intent, in more advanced but potentially curative cancers, treatment for mid and upper third tumours is primarily surgery with extended lymphadenectomy, together with multimodal therapies such as preoperative chemotherapy or chemoradiotherapy. Definitive chemoradiotherapy is utilized in those who decline surgery or in those who are unfit for major procedures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2018.11.012DOI Listing
January 2019
3.478 Impact Factor

Robot assisted minimally invasive esophagectomy (RAMIE) for esophageal cancer.

Best Pract Res Clin Gastroenterol 2018 Oct - Dec;36-37:81-83. Epub 2018 Nov 29.

Department of Surgery, G04.228, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands.

Worldwide, the standard treatment for locally advanced esophageal cancer with curative intent is perioperative chemotherapy or preoperative chemoradiotherapy followed by open transthoracic esophagectomy (OTE) with gastric conduit reconstruction. Minimally invasive esophagectomy (MIE) was developed to improve the postoperative outcome by reducing the surgical trauma, with comparable short-term oncologic results. However, MIE is a highly complex procedure associated with a long learning curve. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2018.11.004DOI Listing
January 2019
1 Read

Oesophagectomy: The expanding role of minimally invasive surgery in oesophageal cancer.

Best Pract Res Clin Gastroenterol 2018 Oct - Dec;36-37:75-80. Epub 2018 Nov 21.

Department of Upper GI Surgery and General Surgery, Norfolk and Norwich University Hospital, Colney Lane, NR4 7UY, Norwich, United Kingdom. Electronic address:

Historically, open oesophagectomy was the gold standard for oesophageal cancer surgery. This was associated with a relatively higher morbidity. In the last two decades, we have seen significant improvements in short and long term outcomes due to centralisation of oesophagectomy, multidisciplinary approach, enhanced recovery after surgery programmes, neoadjuvant treatments and advances in minimally invasive oesophagectomy (MIO) techniques. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2018.11.001DOI Listing
January 2019

Peri-operative patient optimization for oesophageal cancer surgery - From prehabilitation to enhanced recovery.

Best Pract Res Clin Gastroenterol 2018 Oct - Dec;36-37:61-73. Epub 2018 Nov 30.

Department of Gastrointestinal Medicine and Surgery, Guy's and St Thomas' NHS Foundation Trust, London, UK; Division of Cancer Studies, King's College London, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2018.11.006DOI Listing
November 2018

The role of definitive chemoradiation in patients with non-metastatic oesophageal cancer.

Best Pract Res Clin Gastroenterol 2018 Oct - Dec;36-37:53-59. Epub 2018 Nov 21.

Amsterdam University Medical Centers, Cancer Center Amsterdam, Location Academic Medical Center, Department of Radiation Oncology, Meibergdreef 9; B0-107, 1105 AZ, Amsterdam, Netherlands. Electronic address:

Definitive chemoradiation (dCRT) is a curative treatment option for patients with oesophageal cancer. It is effective in both adenocarcinoma and squamous cell carcinoma. However, locoregional control is less after dCRT compared to preoperative CRT (pCRT) followed by surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2018.11.011DOI Listing
January 2019

Chemotherapy and novel targeted therapies for operable esophageal and gastroesophageal junctional cancer.

Best Pract Res Clin Gastroenterol 2018 Oct - Dec;36-37:45-52. Epub 2018 Nov 22.

Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers (UMC) Location AMC, University of Amsterdam, Amsterdam, the Netherlands. Electronic address:

During the past decades, several treatment strategies such as neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy and perioperative chemotherapy have been shown to improve the prognosis of resectable esophageal cancer. Patients with squamous cell tumors respond better to neoadjuvant chemoradiotherapy compared to adenocarcinoma. Therefore, in squamous tumors neoadjuvant chemoradiotherapy is the preferred strategy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2018.11.005DOI Listing
January 2019
1 Read

Neoadjuvant chemoradiotherapy for resectable oesophageal cancer.

Best Pract Res Clin Gastroenterol 2018 Oct - Dec;36-37:37-44. Epub 2018 Nov 22.

Department of Surgery, Erasmus MC - University Medical Centre Rotterdam, Dr. Molenwaterplein 40, 3000 CA, Rotterdam, the Netherlands.

At present, treatment of potentially curable oesophageal cancer includes neoadjuvant chemoradiotherapy followed by oesophagectomy. Alternatively, neoadjuvant chemotherapy is used. To date, strong evidence on the superiority of one modality over the other has not been provided. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2018.11.007DOI Listing
January 2019

Risk factors for oesophageal cancer.

Best Pract Res Clin Gastroenterol 2018 Oct - Dec;36-37:3-8. Epub 2018 Nov 22.

Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; School of Cancer and Pharmaceutical Sciences, King's College London, United Kingdom.

The two main histological subtypes of oesophageal cancer, squamous cell carcinoma and adenocarcinoma, have distinct risk factor profiles. For oesophageal squamous cell carcinoma, tobacco smoking and excess alcohol use are the main risk factors. For adenocarcinoma, gastro-oesophageal reflux disease and obesity are main risk factors, whereas tobacco smoking is a moderately strong risk factor and infection with Helicobacter pylori decreases the risk. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2018.11.008DOI Listing
January 2019

Endoscopic management of dysplasia and early oesophageal cancer.

Best Pract Res Clin Gastroenterol 2018 Oct - Dec;36-37:27-36. Epub 2018 Nov 23.

Dept of Gastroenterology, Guy's & St Thomas' Hospitals NHS Foundation Trust, Westminster Bridge Road, London, SE1 7EH, United Kingdom.

In the past decade there have been technological advances in Endoscopic Eradication Therapy (EET) for the management of patients with oesophageal neoplasia and early cancer. Multiple endoscopic techniques now exist for both squamous and Barrett's oesophagus associated neoplasia or early cancer. A fundamental aspect of endotherapy is removal of the target lesion by endoscopic mucosal resection, or endosopic submucosal dissection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2018.11.003DOI Listing
January 2019
1 Read

Novel imaging techniques in staging oesophageal cancer.

Best Pract Res Clin Gastroenterol 2018 Oct - Dec;36-37:17-25. Epub 2018 Nov 22.

Department of Radiology, Guy's & St Thomas' NHS Foundation Trust, London, UK; School of Biomedical Engineering and Imaging Sciences, King's College, London, UK. Electronic address:

The survival of oesophageal cancer is poor as most patients present with advanced disease. Radiological staging of oesophageal cancer is complex but is fundamental to clinical management. Accurate staging investigations are vitally important to guide treatment decisions and optimise patient outcomes. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15216918183009
Publisher Site
http://dx.doi.org/10.1016/j.bpg.2018.11.009DOI Listing
January 2019
5 Reads

Preface "Oesophageal cancer".

Best Pract Res Clin Gastroenterol 2018 Oct - Dec;36-37

Guy's & St Thomas' NHS Foundation Trust, Westminster Bridge Road, London, SE1 7EH, United Kingdom. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2018.12.001DOI Listing
December 2018

Risk stratification and prognostic modelling in primary biliary cholangitis.

Best Pract Res Clin Gastroenterol 2018 Jun - Aug;34-35:95-106. Epub 2018 Jun 18.

Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands; Toronto Centre for Liver Disease, Toronto General Hospital, Toronto, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada. Electronic address:

Primary biliary cholangitis (PBC) is a slowly progressive chronic cholestatic liver disease that, in a subgroup of patients, may result in liver failure or death. The definition of specific risk profiles, i.e. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15216918183000
Publisher Site
http://dx.doi.org/10.1016/j.bpg.2018.06.006DOI Listing
December 2018
12 Reads

Improving prognosis in primary biliary cholangitis - Therapeutic options and strategy.

Best Pract Res Clin Gastroenterol 2018 Jun - Aug;34-35:85-94. Epub 2018 Jun 14.

Erasmus University Medical Center, Rotterdam, The Netherlands.

Overall survival in primary biliary cholangitis is diminished. As patients are often asymptomatic, the disease may silently progress towards cirrhosis and liver failure. Timely diagnosis and effective treatment options are of vital importance to improve the prognosis of affected patients. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15216918183001
Publisher Site
http://dx.doi.org/10.1016/j.bpg.2018.06.004DOI Listing
December 2018
19 Reads

Patterns of disease progression and incidence of complications in primary biliary cholangitis (PBC).

Best Pract Res Clin Gastroenterol 2018 Jun - Aug;34-35:71-83. Epub 2018 Jun 14.

National Institute for Health Research (NIHR), Birmingham Biomedical Research Centre (BRC), Centre for Liver Research, University of Birmingham, Birmingham, UK; Liver Unit, University Hospitals Birmingham Queen Elizabeth, Birmingham, UK. Electronic address:

Clinical outcome for patients with primary biliary cholangitis (PBC) is dictated by development of cirrhosis, portal hypertension and its associated complications; including for some, a predisposition toward hepatocellular carcinoma. However rates of clinical progression vary, and accurately identifying disease course is of critical importance to patients, clinicians, as well as industry, who are committed to developing new effective and life-prolonging therapy as well as treating symptoms that appear disproportionate to underlying disease severity. Patients seek reassurance and guidance as to their own prognosis, and clinicians wish to confidently recognise those at highest risk of poor outcomes as equally as they strive to reassure individuals with a more favourable disease trajectory. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2018.06.002DOI Listing
December 2018
2 Reads

Primary biliary cholangitis and bone disease.

Best Pract Res Clin Gastroenterol 2018 Jun - Aug;34-35:63-70. Epub 2018 Jun 14.

Department of Rheumatology, Metabolic Bone Diseases Unit, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain.

Osteoporosis, characterized by compromised bone strength leading to fragility fractures, is a common event in patients with primary biliary cholangitis (PBC). Osteomalacia, defined by poor bone mineralization is very uncommon. The pathogenesis of osteoporosis is not well clarified, but it mainly results from low bone formation. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15216918183000
Publisher Site
http://dx.doi.org/10.1016/j.bpg.2018.06.005DOI Listing
December 2018
16 Reads
3.480 Impact Factor

Variant syndromes of primary biliary cholangitis.

Best Pract Res Clin Gastroenterol 2018 Jun - Aug;34-35:55-61. Epub 2018 Jun 14.

I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Patients with primary biliary cholangitis (PBC) can show biochemical, serological and/or histological features of autoimmune hepatitis (AIH). The term 'AIH-PBC overlap syndrome' has been used frequently for these cases and implies the coexistence of two separate diseases. However, the boundaries between 'classical' PBC, PBC with features of AIH and 'classical' AIH are difficult to define, and therefore the term 'variant syndrome' should be preferred. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15216918183002
Publisher Site
http://dx.doi.org/10.1016/j.bpg.2018.06.003DOI Listing
December 2018
26 Reads

PBC and related extrahepatic diseases.

Best Pract Res Clin Gastroenterol 2018 Jun - Aug;34-35:49-54. Epub 2018 May 23.

Dept. of Surgery, Oncology and Gastroenterology, University of Padova, Italy.

Patients with PBC have at least 60% of probability to have an autoimmune extrahepatic condition. The pathogenesis of these conditions includes a common mechanism involving both innate and adaptive immune responses targeting cholangiocytes and different extrahepatic tissues. The recent EASL guidelines recommend the management of these conditions, although detailed practical treatments have not been indicated. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15216918183000
Publisher Site
http://dx.doi.org/10.1016/j.bpg.2018.05.013DOI Listing
December 2018
22 Reads

Symptoms of PBC - Pathophysiology and management.

Best Pract Res Clin Gastroenterol 2018 Jun - Aug;34-35:41-47. Epub 2018 Jun 14.

Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK; NIHR Biomedical Research Centre, Newcastle University, Newcastle upon Tyne, UK. Electronic address:

Primary biliary cholangitis is a chronic cholestatic liver disease characterised by progressive bile duct damage and, ultimately, biliary cirrhosis. Though up to fifty percent of the patients can be asymptomatic at presentation, symptoms when present are frequently debilitating with significant impact on quality of life and functional status. Characteristic symptoms include pruritus, fatigue and an increasingly recognised mild cognitive impairment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2018.06.007DOI Listing
December 2018
2 Reads

Evolution of our understanding of PBC.

Best Pract Res Clin Gastroenterol 2018 Jun - Aug;34-35:3-9. Epub 2018 Jun 15.

Division of Rheumatology Allergy and Clinical Immunology, University of California School of Medicine, Davis, CA, USA. Electronic address:

The discovery of mitochondrial autoantigens recognized by antimitochondrial antibodies (AMAs) in 1987 marked the dawn of a new era in primary biliary cholangitis (PBC) research. Since then, there has been substantial progress in our understanding of PBC partly bestowed by the development of innovative technologies in molecular biology, immunology, and genetics. Here, we review this evolutionary progress in understanding PBC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2018.05.008DOI Listing
December 2018
4 Reads

Is PBC a viral infectious disease?

Authors:
Andrew L Mason

Best Pract Res Clin Gastroenterol 2018 Jun - Aug;34-35:27-39. Epub 2018 Jun 14.

Department of Medicine, University of Alberta, Edmonton, AB, T6G 2E1, Canada. Electronic address:

The human betaretrovirus and the closely related mouse mammary tumor virus have been linked with the development of cholangitis and mitochondrial antibody production in patients with primary biliary cholangitis (PBC) and mouse models of autoimmune biliary disease, respectively. In vitro, betaretroviruses have been found to stimulate the expression of mitochondrial autoantigens on the cell surface of biliary epithelial cells. In vivo, both mitochondrial autoantigens and viral proteins have been shown to be co-expressed in biliary epithelium and lymphoid tissue. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15216918183006
Publisher Site
http://dx.doi.org/10.1016/j.bpg.2018.06.001DOI Listing
December 2018
2 Reads

Pathophysiology of primary biliary cholangitis.

Best Pract Res Clin Gastroenterol 2018 Jun - Aug;34-35:17-25. Epub 2018 May 24.

Centre for Liver Research and NIHR Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, UK. Electronic address:

Primary biliary cholangitis is a prototypical autoimmune disease characterized by an overwhelming female predominance, a distinct clinical phenotype, and disease specific anti-mitochondrial antibodies targeted against a well-defined auto-antigen. In a genetically susceptible host, multi-lineage loss of tolerance to the E2 component of the 2-oxo-dehydrogenase pathway and dysregulated immune pathways directed at biliary epithelial cells leads to cholestasis, progressive biliary fibrosis, and cirrhosis in a subset of patients. Several key insights have shed light on the complex pathogenesis of disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2018.05.012DOI Listing
December 2018
2 Reads

Geoepidemiology and (epi-)genetics in primary biliary cholangitis.

Best Pract Res Clin Gastroenterol 2018 Jun - Aug;34-35:11-15. Epub 2018 May 16.

Division of Gastroenterology and Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy. Electronic address:

Primary biliary cholangitis (PBC) is a rare female preponderant chronic autoimmune cholestatic liver disease, characterized by intrahepatic ductopenia and progressive fibrosis. During last decades incidence and prevalence showed an increasing rate which vary widely worldwide demonstrating an important interaction between environmental and genetic factors. Heritability suggested by familial occurrence and monozygotic twins concordance have been confirmed in more studies. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15216918183005
Publisher Site
http://dx.doi.org/10.1016/j.bpg.2018.05.011DOI Listing
December 2018
12 Reads

PBC-transplantation and disease recurrence.

Authors:
Frederik Nevens

Best Pract Res Clin Gastroenterol 2018 Jun - Aug;34-35:107-111. Epub 2018 Sep 11.

Department of Gastroenterology and Hepatology, University Hospitals KU Leuven, Belgium. Electronic address:

Despite near universal use of ursodeoxycholic acid (UDCA) several patients with PBC still progress to liver transplant (LT) or death. Pruritus and fatigue are the most common symptoms. Liver transplantation for pruritus is highly effective but fatigue will not disappear in the majority of the patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2018.09.001DOI Listing
December 2018
3 Reads

Preface - Primary Biliary Cholangitis.

Best Pract Res Clin Gastroenterol 2018 Jun - Aug;34-35. Epub 2018 Aug 2.

Toronto Centre for Liver disease, Francis Family Liver Clinic, Toronto General Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2018.07.002DOI Listing
August 2018
1 Read

Can IL-23 be a good target for ulcerative colitis?

Best Pract Res Clin Gastroenterol 2018 Feb - Apr;32-33:95-102. Epub 2018 May 23.

IBD Centre, Humanitas Clinical and Research Centre, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy.

A considerable percentage of patients with ulcerative colitis (UC) do not respond to therapies, including anti-tumor necrosis factor (TNF) drugs and vedolizumab, or lose response over time. Hence the continuing need to find new therapeutic strategies and novel drugs to control this chronic debilitating disease. Increased levels of interleukin (IL)-23 and T helper (Th) 17 cell cytokines have been found in intestinal mucosa, plasma, and serum of patients with inflammatory bowel disease (IBD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2018.05.016DOI Listing
September 2018
6 Reads

Can we move directly from 5-ASA to a biologic agent in ulcerative colitis?

Best Pract Res Clin Gastroenterol 2018 Feb - Apr;32-33:9-15. Epub 2018 Jun 20.

Department of Gastroenterology, Ljubljana University Medical Centre, Ljubljana, Slovenia.

European consensus guidelines and reimbursement policies position biologic drugs for ulcerative colitis (UC) as a third-line treatment, after failure of 5-aminosalicylic acid (5-ASA) and corticosteroids/thiopurines. While 5-ASA have a very favorable safety profile, (prolonged) use of corticosteroids and thiopurines is associated with potentially serious adverse events. The therapeutic landscape of UC is rapidly evolving and selective biologic drugs with improved safety are being introduced. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2018.05.004DOI Listing
September 2018

JAK inhibitors: Novel developments in management of ulcerative colitis.

Best Pract Res Clin Gastroenterol 2018 Feb - Apr;32-33:89-93. Epub 2018 May 23.

Humanitas University, Department of Biomedical Sciences, Rozzano, Milan, Italy; Humanitas Clinical and Research Institute, IBD Center, Rozzano, Milan, Italy. Electronic address:

Janus kinase inhibitors are small molecules, orally administered, under development for the treatment of ulcerative colitis. These molecules reduce the immune response, blocking the signal transduction of multiple cytokines implicated in the activation of inflammation. Currently multiple JAK inhibitors are being evaluated in clinical trials. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15216918183005
Publisher Site
http://dx.doi.org/10.1016/j.bpg.2018.05.015DOI Listing
September 2018
17 Reads

The impact of biologics in surgical outcomes in ulcerative colitis.

Best Pract Res Clin Gastroenterol 2018 Feb - Apr;32-33:79-87. Epub 2018 Jun 8.

IBD Center, Department of Gastroenterology, Humanitas Research Hospital, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy. Electronic address:

Ulcerative Colitis (UC) is an immune mediated condition characterized by inflammation of colonic mucosa, associated with progressive damage of the colon and possible complications, such as hemorrhage, perforation and cancer. It is strongly advocated a treat to target approach in patients with UC consisting in an early and aggressive inflammatory control. Some patients can require colectomy for medically refractory disease or to treat colonic neoplasia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2018.05.014DOI Listing
September 2018
26 Reads

Surgery in ulcerative colitis: When? How?

Best Pract Res Clin Gastroenterol 2018 Feb - Apr;32-33:71-78. Epub 2018 Jun 14.

Humanitas University, Department of Biomedical Sciences, Via Manzoni 113, 20089, Rozzano, Milano, Italy; Humanitas Clinical and Research Center, Colon and Rectal Surgery Unit, Via Manzoni 113, 20089, Rozzano, Milano, Italy. Electronic address:

Ulcerative Colitis (UC) is an idiopathic chronically-remitting inflammatory bowel disorder characterized by a contiguous inflammation of the colonic mucosa affecting the rectum that generally extends proximally in a continuous manner through the entire colon. Patients typically experience intermittent exacerbations, with symptoms characterized by bloody diarrhea associated with urgency and tenesmus. The anatomical extent of mucosal involvement is the most important factor determining disease course and is an important predictor of colectomy. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15216918183002
Publisher Site
http://dx.doi.org/10.1016/j.bpg.2018.05.017DOI Listing
September 2018
5 Reads

Acute severe ulcerative colitis: State of the art treatment.

Best Pract Res Clin Gastroenterol 2018 Feb - Apr;32-33:59-69. Epub 2018 May 12.

Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.

Acute severe ulcerative colitis (ASUC) is a potentially life-threatening condition. In the present review, we give a broad overview of the state of the art in the management of this condition. A systematic bibliographic search was performed in PubMed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2018.05.007DOI Listing
September 2018
1 Read

The treatment of refractory ulcerative colitis.

Best Pract Res Clin Gastroenterol 2018 Feb - Apr;32-33:49-57. Epub 2018 May 18.

Department of Gastroenterology, Saint-Eloi Hospital, Montpellier University Hospital, Montpellier University, Montpellier, France.

Ulcerative proctitis is defined as a mucosal inflammation limited to the rectum. Ulcerative proctitis is responsible for distressing symptoms and alteration of patient quality of life. Effective treatment is important to prevent or delay proximal extension of the disease and to improve quality of life. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15216918183002
Publisher Site
http://dx.doi.org/10.1016/j.bpg.2018.05.009DOI Listing
September 2018
20 Reads

Safety of biological therapies in ulcerative colitis: An umbrella review of meta-analyses.

Best Pract Res Clin Gastroenterol 2018 Feb - Apr;32-33:43-47. Epub 2018 Jun 11.

Department of Biomedical Sciences, Humanitas University, 20090, Pieve Emanuele, Milan, Italy; IBD Center, Humanitas Clinical and Research Center, 20089, Rozzano, Milan, Italy. Electronic address:

Biological agents have proven clinical efficacy in the treatment of ulcerative colitis (UC). Their adverse effects have also been studied in a substantial number of primary studies and meta-analyses. Given the large volume of information that has been published, the aim of this umbrella review was to effectively summarize the accumulated evidence from randomized controlled trials (RCTs) on the safety of biological therapies for UC into one accessible and usable document. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15216918183000
Publisher Site
http://dx.doi.org/10.1016/j.bpg.2018.05.005DOI Listing
September 2018
16 Reads

Biosimilars in ulcerative colitis: When and for who?

Best Pract Res Clin Gastroenterol 2018 Feb - Apr;32-33:35-42. Epub 2018 May 26.

Semmelweis University, First Department of Internal Medicine, Budapest, Hungary; McGill University, Division of Gastroenterology, Montreal, Canada. Electronic address:

The introduction of biological agents has revolutionized the management of ulcerative colitis (UC). Biosimilars are considered to be equivalent to the reference biologic products in terms of pharmacokinetic properties, clinical effectiveness and safety and have now been approved in inflammatory bowel diseases (IBD). CT-P13 was the first biosimilar to infliximab that obtained regulatory approval by the EMA and US FDA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2018.05.003DOI Listing
September 2018
1 Read

Which evidence for a treat to target strategy in ulcerative colitis?

Best Pract Res Clin Gastroenterol 2018 Feb - Apr;32-33:3-8. Epub 2018 May 12.

Department of Pathology, University Hospital of Reims, 51100, Reims, France. Electronic address:

The main therapeutic goal of in ulcerative colitis is to maintain disease remission. The new concept of deep remission implies also a complete mucosal healing. Histological assessment of disease in UC seems to be an important prognostic factor to predict disease outcome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2018.05.001DOI Listing
September 2018
1 Read

Should we use vedolizumab as mono or combo therapy in ulcerative colitis?

Best Pract Res Clin Gastroenterol 2018 Feb - Apr;32-33:27-34. Epub 2018 May 12.

Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, SE 70182, Örebro, Sweden. Electronic address:

Randomized controlled trials comparing the efficacy of vedolizumab monotherapy with combination therapy of vedolizumab and an immunomodulator in patients with ulcerative colitis (UC) are lacking. Emerging pharmacokinetic data indicate that vedolizumab concentrations correlate with clinical outcomes, although the correlation may be less strong for vedolizumab compared with an anti-TNF agents. Associations between concomitant use of immunomodulators and decreased immunogenicity of vedolizumab have been reported, but this does not appear to translate into enhanced therapeutic effect of combination therapy, at least not based on present data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2018.05.002DOI Listing
September 2018

Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?

Best Pract Res Clin Gastroenterol 2018 Feb - Apr;32-33:17-25. Epub 2018 May 12.

Department of Gastroenterology, Nancy University Hospital, Université de Lorraine, 1 Allée du Morvan, 54511, Vandoeuvre-lès-Nancy, France.

Randomized controlled trials with direct comparisons between the different available biological agents in ulcerative colitis are lacking. The comparative efficacy, safety and tolerability, patient profile, patient preference and costs should be taken into account when choosing an appropriate first-line biological. Tumor necrosis factor antagonists have a systemic mode of action, while vedolizumab is mainly gut-selective, and this influences the clinical profile of both treatment options. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2018.05.006DOI Listing
September 2018
21 Reads

Colorectal cancer prevention in patients with ulcerative colitis.

Best Pract Res Clin Gastroenterol 2018 Feb - Apr;32-33:103-109. Epub 2018 May 16.

Department of Gastroenterology and NGERE Unit, Inserm, University Hospital of Nancy, Lorraine University, Vandoeuvre-lès-Nancy, France.

Ulcerative colitis is characterized by chronic inflammation, which may lead to the accumulation of high levels of pro-inflammatory cytokines within the colonic mucosa, and thus to dysplastic lesions and cancer. Although the trend is decreasing, ulcerative colitis patients still have a 2.4 fold higher risk of colorectal cancer compared to the general population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2018.05.010DOI Listing
September 2018
26 Reads

Evolving strategies and goals of treatment in ulcerative colitis.

Best Pract Res Clin Gastroenterol 2018 Feb - Apr;32-33:1-2

IBD Centre, Humanitas Clinical and Research Centre, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2018.07.001DOI Listing
August 2018
17 Reads

Intervening in disease through genetically-modified bacteria.

Best Pract Res Clin Gastroenterol 2017 Dec 25;31(6):693-697. Epub 2017 Sep 25.

Epiexpressions, Rotterdam, Netherlands. Electronic address:

The comprehension of the molecular basis of different diseases is rapidly being dissected as a consequence of advancing technology. Consequently, proteins with potential therapeutic usefulness, including cytokines and signaling molecules have been identified in the last decades. However, their clinical use is hampered by disadvantageous functional and economic considerations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2017.09.017DOI Listing
December 2017
2 Reads

Microbiome, pattern recognition receptor function in health and inflammation.

Best Pract Res Clin Gastroenterol 2017 Dec 21;31(6):683-691. Epub 2017 Nov 21.

MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DS, UK; Translational Gastroenterology Unit, Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK. Electronic address:

The innate immune system plays an important role in shaping the microbiota into configurations that are tolerated and beneficial to the host, thereby playing a crucial role in human health. Innate immunity is based on the fundamental principle that Pattern Recognition Receptors (PRRs) recognise pathogen associated molecular patterns as non-self-entities and trigger intracellular signalling pathways that lead to the induction of numerous cytokines and chemokines that help maintain host resistance to infections. Dysregulation of this interaction has been identified as the core defect that leads to chronic intestinal inflammation allowing certain microbiota to be harmful to host health. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2017.11.001DOI Listing
December 2017
3 Reads

Diet, microbiome, and colorectal cancer.

Best Pract Res Clin Gastroenterol 2017 Dec 5;31(6):675-681. Epub 2017 Sep 5.

Department of Gasteroenterology and Hepatology, Erasmus MC - University Medical Center Rotterdam, 's Gravendijkwal 230, NL-3015, CE Rotterdam, The Netherlands. Electronic address:

The scientific interests in the colorectal cancer (CRC) associated microbiome have increased significantly in the past decade. Mechanistically, several members of the human microbiome and products thereof have been implicated as inductors of the pathogenic inflammation related to CRC. Conversely, the activities of the human intestinal microbial community influenced by specific diet might confer a protective effect against the CRC risks and progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2017.09.007DOI Listing
December 2017

Intestinal microbiome and permeability in patients with autoimmune hepatitis.

Best Pract Res Clin Gastroenterol 2017 Dec 18;31(6):669-673. Epub 2017 Sep 18.

Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin 300052, PR China. Electronic address:

Autoimmune hepatitis (AIH) is a severe inflammatory liver disease. The underlying mechanisms remain unclear, but recent studies provided new perspectives on altered intestinal microbiome and permeability in AIH animal models and patients, highlighting gut-liver crosstalk in the pathogenesis of AIH. Transgenic AIH mice carrying HLA-DR3 showed reduced diversity and total load of gut microbiota. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15216918173010
Publisher Site
http://dx.doi.org/10.1016/j.bpg.2017.09.013DOI Listing
December 2017
14 Reads

NAFLD, Helicobacter species and the intestinal microbiome.

Best Pract Res Clin Gastroenterol 2017 Dec 5;31(6):657-668. Epub 2017 Sep 5.

School of Medical Sciences, UNSW Sydney, Sydney, NSW, 2052, Australia.

Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide. It is well-accepted that gut dysbiosis is associated with NAFLD, however, there is some conflicting evidence regarding the nature of these alterations. Infection with Helicobacter species, mainly H. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2017.09.008DOI Listing
December 2017
7 Reads

Action and function of Chromobacterium violaceum in health and disease: Violacein as a promising metabolite to counteract gastroenterological diseases.

Best Pract Res Clin Gastroenterol 2017 Dec 12;31(6):649-656. Epub 2017 Oct 12.

Biological Chemistry Laboratory, Institute of Chemistry, Universidade Estadual de Campinas, CP 6154, 13083-970, Campinas, SP, Brazil; NanoBioss, Institute of Chemistry, Universidade Estadual de Campinas, Campinas, SP, Brazil; LNNano (CNPEM), Campinas, SP, Brazil. Electronic address:

Chromobacterium violaceum is a Gram negative, β-proteobacterium found in the microbiota of tropical and subtropical environments. Although considered an opportunistic pathogen, infection rapidly progress to fatal sepsis, with metastatic abscesses. It is noteworthy the multidrug resistant phenotype of C. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2017.10.002DOI Listing
December 2017
2 Reads

Action and function of Faecalibacterium prausnitzii in health and disease.

Best Pract Res Clin Gastroenterol 2017 Dec 18;31(6):643-648. Epub 2017 Sep 18.

Plateinnove Biotechnology, Piracicaba, São Paulo, Brazil. Electronic address:

Faecalibacterium prausnitzii, anaerobic bacteria, is one of the main components of gut microbiota and the most important butyrate-producing bacteria in the human colon. So far, this commensal bacterium has been considered as a bioindicator of human health, once when its population is altered (decreased), inflammatory processes are favored. Several reports in the literature highlighted that the amount of Faecalibacterium prausnitzii negatively correlates to the activity of inflammatory bowel disease and colorectal cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2017.09.011DOI Listing
December 2017
2 Reads

Action and function of Akkermansia muciniphila in microbiome ecology, health and disease.

Best Pract Res Clin Gastroenterol 2017 Dec 13;31(6):637-642. Epub 2017 Oct 13.

Wageningen University and Research, Stippeneng 4, 6708WE Wageningen, The Netherlands. Electronic address:

The discovery of Akkermansia muciniphila has opened new avenues for the use of this abundant intestinal symbiont in next generation therapeutic products, as well as targeting microbiota dynamics. A. muciniphila is known to colonize the mucosal layer of the human intestine where it triggers both host metabolic and immune responses. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15216918173011
Publisher Site
http://dx.doi.org/10.1016/j.bpg.2017.10.001DOI Listing
December 2017
5 Reads

Lifestyle alters GUT-bacteria function: Linking immune response and host.

Best Pract Res Clin Gastroenterol 2017 Dec 6;31(6):625-635. Epub 2017 Sep 6.

Department of Gastroenterology-Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands; Department of Cell Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Electronic address:

Microbiota in human is a "mixture society" of different species (i.e. bacteria, viruses, funguses) populations with a different way of relationship classification to Human. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2017.09.009DOI Listing
December 2017
3 Reads